ACXP

Acurx Pharmaceuticals Inc

1.06

Nov 03 • 10:19 AM ET -0.01 (-0.93%)

Healthcare Biotechnology USA Nano NASD

Peers: MCRB TOVX SPRO ARMP CRMD SNGX PYPD SXTP IMRN COCP

Index	-
Market Cap	5.89M
Enterprise Value	-4.77M
Income	-7.51M
Sales	0.00M
Book/sh	1.74
Cash/sh	1.92
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	4
IPO	Jun 25, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.61
P/C	0.55
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	3.88
Current Ratio	3.88
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-3.05
EPS next Y	-1.50
EPS next Q	-0.38
EPS this Y	67.67%
EPS next Y	12.79%
EPS next 5Y	31.04%
EPS past 3/5Y	38.05% 10.54%
Sales past 3/5Y	- -
EPS Y/Y TTM	71.66%
Sales Y/Y TTM	-
EPS Q/Q	71.96%
Sales Q/Q	-
Earnings	Nov 12 BMO
EPS/Sales Surpr.	-40.70% -

Insider Own	8.12%
Insider Trans	0.00%
Inst Own	2.40%
Inst Trans	4.07%
ROA	-87.57%
ROE	-128.11%
ROIC	-92.08%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-7.33%
SMA50	-17.31%
SMA200	-45.91%
Trades

Shs Outstand	5.56M
Shs Float	5.11M
Short Float	1.78%
Short Ratio	0.75
Short Interest	0.09M
52W High	7.54 -85.94%
52W Low	1.03 2.43%
Volatility	5.13% 5.18%
ATR (14)	0.06
RSI (14)	32.00
Beta	-2.09
Rel Volume	2.96
Avg Volume	120.68K
Volume	67,439

Perf Week	0.01%
Perf Month	-19.08%
Perf Quarter	-27.88%
Perf Half Y	-47.00%
Perf YTD	-57.43%
Perf Year	-79.05%
Perf 3Y	-98.38%
Perf 5Y	-99.03%
Perf 10Y	-
Recom	1.00
Target Price	17.00
Prev Close	1.07
Price	1.06
Change %	-0.93%

Oct-26-26 08:01AM	Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update (PR Newswire)
Oct-21-26 08:01AM	Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect (PR Newswire)
Sep-29-26 08:01AM	Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection (PR Newswire)
Sep-14-26 08:01AM	Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and Vancomycin-Resistant Enterococcus Co-Cultures (PR Newswire)
Aug-20-26 09:02PM	Acurx Pharmaceuticals Inc (ACXP) (Q2 2026) Earnings Call Highlights: FDA Signals Potential ... (GuruFocus.com)
08:01AM	Loading…
Aug-17-26 08:01AM	Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat (PR Newswire) +18.28%
Aug-14-26 07:01AM	Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update (PR Newswire) -5.74%
Aug-12-26 08:01AM	Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics (PR Newswire)
Aug-10-26 08:01AM	Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics (PR Newswire)
Aug-03-26 08:00AM	FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection (PR Newswire)
Jul-14-26 08:00AM	Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection (PR Newswire)
Jul-08-26 08:00AM	Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update (PR Newswire) -6.21%
Jun-16-26 08:00AM	Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference (PR Newswire)
May-12-26 07:01AM	Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update (PR Newswire) -5.96%
May-04-26 08:00AM	Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026 (PR Newswire)
08:00AM	Loading…
Apr-29-26 08:00AM	Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase (PR Newswire)
Apr-27-26 08:00AM	Acurx Pharmaceuticals, Inc. To Present at The Market Movers Investor Summit (Newsfile)
Apr-20-26 08:00AM	Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update (PR Newswire)
Apr-16-26 04:01PM	Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (PR Newswire) -19.68%
08:00AM	Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (PR Newswire)
Mar-30-26 07:01AM	Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors (PR Newswire) -6.91%
Mar-23-26 09:00PM	Acurx Pharmaceuticals Inc (ACXP) Q4 2025 Earnings Call Highlights: Financial Growth and ... (GuruFocus.com) -19.20% -5.41%
Mar-13-26 07:01AM	Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update (PR Newswire) -22.55%
Mar-09-26 08:01AM	Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection (PR Newswire) +44.81%
Feb-24-26 01:12PM	Acurx Pharmaceuticals (ACXP) Secures New US Patent for DNA Polymerase IIIC Inhibitors (Insider Monkey)
Feb-16-26 08:01AM	Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update (PR Newswire)
Feb-02-26 08:00AM	USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors (PR Newswire)
Jan-06-26 09:40AM	Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year? (Zacks)
Nov-18-25 08:00AM	Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals (PR Newswire)
Nov-12-25 07:01AM	Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update (PR Newswire) -10.75%
08:00AM	Loading…
Nov-10-25 08:00AM	Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens (PR Newswire) +10.99%
Oct-28-25 08:00AM	Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference (PR Newswire)
Oct-27-25 08:00AM	Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update (PR Newswire)
Oct-09-25 07:30AM	Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors (PR Newswire) -8.15%
Aug-12-25 07:01AM	Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update (PR Newswire)
Jul-31-25 09:25AM	Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split (PR Newswire)
Jul-24-25 07:01AM	Acurx Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 12, 2025 Conference Call and Provide Business Update (PR Newswire)
Jun-18-25 08:00PM	/C O R R E C T I O N -- Acurx Pharmaceuticals, Inc./ (PR Newswire) -12.27% -23.61%
09:40AM	Are Medical Stocks Lagging Acurx Pharmaceuticals (ACXP) This Year? (Zacks)
Jun-17-25 09:47PM	Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds (PR Newswire) +167.24%
07:01AM	Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI (PR Newswire)
Jun-09-25 07:30AM	Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental Biology Scientific Conference (PR Newswire)
May-13-25 07:01AM	Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update (PR Newswire)
May-07-25 12:42PM	Waters Q1 Earnings Surpass Estimates, Revenue Rise Y/Y (Zacks)
Apr-30-25 07:30AM	Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update (PR Newswire)
Apr-28-25 07:30AM	Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase (PR Newswire)
Apr-17-25 07:30AM	Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors (PR Newswire)
Apr-08-25 09:55AM	Acurx Pharmaceuticals (ACXP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks) -7.07%
Apr-02-25 03:30PM	Acurx Pharmaceuticals, Inc. (ACXP): Insider Were Buying In Q1 2025 (Insider Monkey) -5.35%
Mar-23-25 09:00PM	Acurx Pharmaceuticals Inc (ACXP) Q4 2024 Earnings Call Highlights: Advancing Antibiotic Trials ... (GuruFocus.com)
Mar-21-25 12:00PM	Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's What You Should Know (Zacks)
Mar-18-25 07:01AM	Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update (PR Newswire) -14.23%
Mar-14-25 01:10PM	New to The Street & Sight & Sound's Visionaries Series Premieres Tomorrow on Bloomberg at 6:30 PM EST, Featuring Acurx Pharmaceuticals NASDAQ:ACXP (ACCESS Newswire)
Mar-10-25 04:30PM	Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct Offering (PR Newswire)
Mar-07-25 08:00AM	Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering (PR Newswire) -29.86%
Mar-03-25 08:00AM	Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics (PR Newswire) -5.53%
Feb-28-25 08:00AM	Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update (PR Newswire)
Feb-24-25 08:00AM	Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI (PR Newswire) +8.33%
Feb-19-25 08:00AM	JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors (PR Newswire)
Feb-15-25 09:35AM	New to the Street to Broadcast Show 627 on Bloomberg Television at 6:30 PM EST Today as Sponsored Programming (ACCESS Newswire)
Jan-07-25 05:00PM	Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire) -26.01% -6.88%
Jan-06-25 05:35PM	Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire) +22.49%
08:30AM	Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI) (PR Newswire)
Dec-11-24 11:00AM	Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025 (ACCESSWIRE)
Dec-09-24 08:00AM	Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications (PR Newswire) +18.00%
Nov-28-24 09:55AM	Here's Why Acurx Pharmaceuticals (ACXP) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Nov-27-24 07:00AM	DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025 (ACCESSWIRE)
Nov-22-24 12:25PM	MicroStrategy Copycats Are Buying Bitcoin as Price Nears $100,000 (Barrons.com)
Nov-21-24 04:21PM	Bitcoin Briefly Eclipses $99K Why Investors Just Can't Get Enough (Investopedia) -6.47%
Nov-20-24 07:01AM	Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset (PR Newswire) -16.77%
Nov-18-24 07:00AM	Acurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data Update (PR Newswire)
Nov-14-24 02:07AM	Acurx Pharmaceuticals Inc (ACXP) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Nov-13-24 07:00AM	Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update (PR Newswire)
Oct-31-24 03:00PM	New to The Street to Air as Sponsored Programming on Bloomberg Friday, November 1st, Featuring Modular Medical, OriginClear With Shark Tank's Kevin Harrington, Acurx Pharmaceuticals, the Sustainable Green Team, and SEKURs "Hack of the Week" (ACCESSWIRE)
Oct-28-24 10:00AM	New to The Street on Fox Business Premieres Exclusive Sponsored Programming Tonight Featuring Modular Medical (NASDAQ:MODD), Acurx Pharmaceuticals (NASDAQ:ACXP), and LightPath Technologies (NASDAQ:LPTH) (ACCESSWIRE)
Oct-21-24 07:00AM	Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference (PR Newswire)
Oct-17-24 08:00AM	Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor Engagement (PR Newswire)
Oct-16-24 08:00AM	Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024 (PR Newswire)
Oct-14-24 01:00PM	New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Support (ACCESSWIRE)
Oct-11-24 11:05AM	New to the Street Announces Exclusive Bloomberg Lineup for Saturday October 12 at 6:30 PM EST (ACCESSWIRE)
10:50AM	New to the Street Announces Exclusive Bloomberg Lineup for October 11 at 6:30 PM EST (ACCESSWIRE)
Sep-26-24 07:00AM	Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues (PR Newswire) +5.35%
Sep-24-24 07:00AM	Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium (PR Newswire)
Sep-09-24 08:30AM	New to the Street Announces Its Five Corporate Interviews, Airing Episode 599 on the Fox Business Network, Tonight Monday, September 9, 2024, at 10:30 PM PT September 9, 2024 09:15 ET (ACCESSWIRE)
Aug-26-24 09:15AM	New to The Street Announces its Five Corporate Interviews, Airing Episode 591 on the Fox Business Network, Tonight Monday, August 26, 2024, at 10:30 PM PT (GlobeNewswire)
07:00AM	ACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire)
Aug-19-24 09:20AM	New to The Street Announces Episode 590, Five Corporate Interviews, Airing on the Fox Business Network, Tonight Monday, August 19, 2024, at 10:30 PM PT (GlobeNewswire) +5.47%
Aug-10-24 08:18AM	Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q2 2024 Earnings Call Transcript (Insider Monkey)
Aug-09-24 09:30AM	New to The Street TV Announces Episode 583, Five Riveting Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Saturday, August 10, 2024, at 6:30 PM ET (GlobeNewswire)
07:01AM	Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update (PR Newswire)
Jul-17-24 07:00AM	USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome (PR Newswire) +6.07%
Jul-16-24 07:00AM	Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update (PR Newswire)
Jul-15-24 07:00AM	Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference (PR Newswire)
Jun-06-24 09:30AM	New to The Street Announces Episode 576, Four Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Tonight, Thursday, June 6, 2024, at 9:30 PM PT (GlobeNewswire)
May-16-24 03:00AM	Acurx Pharmaceuticals Inc (ACXP) Q1 2024 Earnings Call Transcript Highlights: Key Financial and ... (GuruFocus.com)
May-15-24 10:40PM	Q1 2024 Acurx Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +7.66%
09:53AM	ACXP Stock Earnings: Acurx Pharmaceuticals Misses EPS for Q1 2024 (InvestorPlace)
09:00AM	Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection (PR Newswire)
07:00AM	Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update (PR Newswire)

Show Previous News

Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. Its approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme. Its research and development pipeline includes early-stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus and Penicillin-Resistant Streptococcus pneumoniae. The company was founded by David P. Luci, Robert G. Shawah and Robert J. DeLuccia in July 2017 and is headquartered in New York, NY.

Co-Founder & Executive ChairmanMr. Robert J. DeLuccia

Co-Founder & CFOMr. Robert G. Shawah CPA

F.A.C.P.Dr. Michael H. Silverman B.Sc.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACXP

Acurx Pharmaceuticals Inc

Upgrade your Finviz experience